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Cyclin-dependent kinase 5 (CDK5) is a multifunc-
tional enzyme that plays numerous roles, notably in
brain development. CDK5 is activated through its
association with the activators, p35 and p39, rather
than by cyclins. Proteolytic procession of the N-ter-
minal part of its activators has been linked to Alz-
heimer’s disease and various other neuropathies.
The interaction with the proteolytic product p25 pro-
longs CDK5 activation and modifies the substrate
specificity. In order to discover small-molecule inhib-
itors of the interaction between CDK5 and p25,
we have used a bioluminescence resonance energy
transfer (BRET)-based screening assay. Among the
1,760 compounds screened, the generic drug tamox-
ifen has been identified. The inhibition of the CDK5
activity by tamoxifen was notably validated by moni-
toring the phosphorylation state of tau protein. The
study of the molecular mechanism of inhibition indi-
cates that tamoxifen interacts with p25 to block the
CDK5/p25 interaction and pave the way for new
treatments of tauopathies.
INTRODUCTION
More than 35 million people are estimated to be living with de-
mentia worldwide. By 2015, this number is projected to reach
115+ million (Feldman et al., 2014). This corresponds to the
current population of France and Spain. For the World Health
Organization, it represents a public health priority. Among neuro-
degenerative dementias, the most common is Alzheimer’s dis-
ease (AD). Neuropathological hallmarks for AD are: (1) extensive
cell death; (2) extracellular deposits of amyloid (neuritic) plaques
composed of b-amyloid (Ab) peptides; (3) intraneuronal aggre-472 Chemistry & Biology 22, 472–482, April 23, 2015 ª2015 Elseviergates of hyperphosphorylated tau, a microtubule-associated
protein (Cruz and Tsai, 2004). The first description was pre-
sented in 1906 by Dr. Alois Alzheimer on the brain of his patient,
Auguste Deter. Despite over a century of extensive research
(5,000 research articles related to AD per year on PubMed) and
the massive impact on our societies, effective treatments remain
to be discovered. Current therapies (e.g. based on cholines-
terase inhibition) are only symptomatic with a modest effect
(Feldman et al., 2014). Therapeutic strategies directed toward
the molecular bases of AD include the inhibition of tau hyper-
phosphorylation because it has been shown that tau pathology
is related to neuronal loss (Cohen et al., 2013). One of the major
tau kinases is cyclin-dependent kinase 5 (CDK5), a member of
the serine/threonine kinase family of cyclin-dependent kinases.
Contrary to most CDKs that are implicated in the regulation of
the cell division cycle, CDK5 plays a crucial role during the devel-
opment of the CNS, notably by regulating neuronal migration
(Malumbres and Barbacid, 2005; Smith et al., 2001). Disruption
of the CDK5 locus in mice results in lesions in the CNS associ-
ated with perinatal mortality (Ohshima et al., 1996). CDK5 is a
catalytic subunit that has no enzymatic activity as a monomer.
It is activated by binding to its activating subunits, p35 or p39,
which are structurally related to cyclins (activators of cell-cycle
CDKs) but display no homology at the amino acid level with these
activators (Tarricone et al., 2001). In contrast to the other CDKs,
full CDK5 activation does not require phosphorylation of the acti-
vation loop (Dhavan and Tsai, 2001). Studies have shown that
neurotoxicity induces proteolytic cleavage of the p35 subunit
by calcium-regulated calpains (Lee et al., 2000). The binding of
CDK5 to the N-terminal truncated product p25, so-called neuro-
toxic activator, stabilizes the active dimer, changes the cellular
location, and alters its substrate specificity promoting neurode-
generation (Patrick et al., 1999). In vitro experiments have shown
that the conversion of p35 to p25 does not change significantly
the steady-state kinetic parameters of tau or histone H1 phos-
phorylation by CDK5 (Peterson et al., 2010).
CDK5 is ubiquitously expressed but its activity is restricted to
tissues expressing its regulators p35/p39 and their truncatedLtd All rights reserved
versions. Originally considered as a brain kinase, CDK5 kinase
activity is not restricted to post-mitotic neurons and was notably
observed in various pancreatic cancer cell lines (Feldmann et al.,
2010; Lew et al., 1992), invasive breast cancer cells (Goodyear
and Sharma, 2007), and others (for review see Contreras-Valle-
jos et al., 2012).
In view of these implications of CDK5 kinase activity in both
neurodegenerative disease and cancer, two of the most impor-
tant diseases in the 21st century, CDK5 is an attractive target
to discover new therapeutic treatments. Small molecular weight
inhibitors of CDK5 have been described, including roscovitine,
diaminothiazoles, aloisines, and indirubines (Laha et al., 2011;
Meijer et al., 1997; Mettey et al., 2003; Polychronopoulos et al.,
2004). Co-crystallization experiments have shown that these in-
hibitors act by direct competition with ATP for binding to the cat-
alytic cleft. This is also the case for almost all kinase inhibitors on
the market (Bharate et al., 2013). Target selectivity remains a
formidable challenge in drug development to tackle the appear-
ance of deleterious side effects during treatment. This first gen-
eration of inhibitors might, in principle, be able to interact in vivo
with some of the 2,000 ATP-utilizing enzymes present in the hu-
man proteome, including 518+ kinases, and with the numerous
other nucleotide-binding proteins (for review see Guiffant et al.,
2007). Hence, there is a great need for next-class kinase inhibi-
tors that work through alternative mechanisms leading to higher
target specificity.
A completely different approach can be used for the charac-
terization of highly specific kinase inhibitors. The aim of this
promising alternative avenue is to discover molecules that
disrupt protein interactions involving protein kinases. We have
recently developed and used a bioluminescence resonance en-
ergy transfer (BRET)-based screening assay (reviewed in Bacart
et al., 2008) in yeast to discover first-in-class small-molecule
inhibitors of the interaction betweenCDK5 and its activating sub-
unit, p25 (Corbel et al., 2011). Here, we report the characteriza-
tion of tamoxifen as new a CDK5/p25 interaction inhibitor from
BRET-based screening of the Prestwick Chemical Library, a
library composed of 100% marketed drugs with diverse clinical
applications, thus representing a high degree of ‘‘drug-likeness’’.
Our experiments show inhibition of the catalytic activity of CDK5
by binding of tamoxifen (TMX) on the neurotoxic activator, p25,
opening up a new therapeutic perspective on the oldest and
most-prescribed hormone therapy for breast cancer.
RESULTS
Tamoxifen (TMX) Inhibits Both CDK5/p25 andCDK5/p35
Protein-Protein Interactions
In order to characterize small chemical inhibitors of the interac-
tion between CDK5 and its activating subunit, p25, we have
used a BRET-based screening assay on the budding yeast
Saccharomyces cerevisiae, which we developed previously
(Corbel et al., 2011). In the presence of a substrate, biolumines-
cence from luciferase (Renilla luciferase, RLuc) excites the
acceptor fluorophore (yellow fluorescent protein [YFP]) if the
donor and acceptor are 10–100 A˚ apart, thus monitoring the mo-
lecular interaction between the fused proteins p25 and CDK5,
respectively (Figure 1A). We previously showed that the BRET
signal obtained is specific for the CDK5/p25 interaction; we esti-Chemistry & Biology 22,mated the signal/background (S/B) ratio to be10 (Corbel et al.,
2011). The unspecific background of the BRET signal is mainly
due to stochastic interactions between the donor and the
acceptor inside the cells (Bacart et al., 2008). Hence, the BRET
signal detected in yeast (225 mBRET, Figure 1B) coexpressing
CDK5-YFP and p25-RLuc fusion proteins appeared specific
and robust enough to enable screening of chemical collections.
Moreover, as already described (Corbel et al., 2011), we used
inducible promoters such as the GAL promoter to enable the
small molecules to first interact with one of the two partners prior
to CDK5-YFP/p25-RLuc heterodimer formation. Screening small
molecules against non-preformed protein complexes is likely to
increase the hit rates (Hamdi and Colas, 2012). We screened the
Prestwick Chemical Library composed of 100% approved drugs
(US Food and Drug Administration, European Medicines
Agency, and other agencies) for which bioavailability and toxicity
studies have already been carried out in humans; therefore if
bioactive hits have sufficient affinity for the target, they could
be tested immediately in patients. The hit rate of the BRET-based
screening was low (only one hit from the 880 molecules tested,
corresponding to 0.1%), indicative of the specificity and
the stringency levels of the screening assay. Independently,
TMX was also identified as a hit by the screening of a mecha-
nistic diversity set (which consists of 879 compounds) provided
by the National Cancer Institute (NCI). In comparison with the
control treatment (DMSO), the BRET signalmeasured decreased
by 28.6% (±13.9%, p < 0.01) in the presence of 40 mM TMX.
The inactive compound (InaCpd), used here as a negative result,
is 17b-estradiol, a chemical compound functionally close to
TMX but structurally different. The p25 protein results from the
proteolytic cleavage of p35. In order to monitor the interaction
between CDK5 and p35, a similar BRET assay in yeast was
used (described in Corbel et al., 2011). As shown in Figure 1B,
TMX was also able to inhibit the CDK5/p35 interaction
(–48.7% ± 5.98% [p < 0.01] of the BRET signal in the presence
of 40 mM drug). As for the CDK5/p25 interaction, InaCpd has
much less effect on CDK5/p35 than TMX (–9.4% ± 3.9% of con-
trol; p < 0.05).
In order to confirm the inhibition of the CDK5/p25 interac-
tion by TMX, we next performed glutathione S-transferase
(GST) pull-down assays on recombinant proteins, in the pres-
ence of increasing concentrations of the molecule. Similar to
the BRET-based screening assay, TMX was first added on one
monomer (here on 6xHis-p25) and not directly on the dimer. In
line with the effect on BRET, TMX inhibited the interaction be-
tween GST-CDK5 and 6xHis-p25 in a dose-dependent way (Fig-
ure 1C). Quantification of the band intensities indicated that 7 mM
TMX was able to inhibit half of the 6xHis-p25 binding to GST-
CDK5 in this assay.
As neuroblastoma cell lines have already been shown to
express p35 (Lee and Kim, 2004), they were chosen to validate
the cellular effect of TMX. Expressions of p35, p25, CDK5,
and tau were then checked in nine neuroblastoma cell lines
(SH-SY5Y, SK-N-AS, SK-N-SH, SK-N-BE(2), LAN-1, LAN-5,
BMMOA, IMR-32, and IGR-N-91). Among these, none ex-
pressed the cleaved protein p25 and only three simultaneously
expressed a detectable amount of p35, CDK5, and one key pro-
tein substrate, the tau isoforms (Figure S1). The SK-N-BE(2) cell
line was then selected by taking into account the expression472–482, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 473
Figure 1. TMX Inhibits CDK5/p25 Interaction
(A) Schematic representation of the BRET-based screening assay (SCC, small chemical compound from a chemical library).
(B) BRET values obtained for yeast strains expressing CDK5-YFP and p25-RLuc or CDK5-YFP and p35-RLuc fusion proteins and treated with 1% DMSO, 40 mM
TMX, or 40 mM inactive compound, InaCpd (mean ± SD, error bars represent SD, n = 3). Significance levels are *p < 0.05; **p < 0.01; n.s., not significant.
(C) Extracts of bacteria expressing 6xHis-p25 (28kDa) were incubated in the presence of increasing doses of TMX (5–50 mM TMX in 1% DMSO) or DMSO (1%)
during 10 min at 4C before adding GST-CDK5 (59 kDa) for 10 min at 4C. The GST-CDK5/6xHis-p25 complexes were purified on glutathione affinity gel and
analyzed by SDS-PAGE followed bywestern blotting using antibodies directed against p25 andGST. Recombinant GST (26 kDa) (first lane on the left side) is used
here to characterize the unspecific binding of 6xHis-p25.
(D) Crude protein extracts of the SK-N-BE(2) cell line co-treated with DMSO (0.25%) or TMX (25 mM) and MG132 (30 mM) (an inhibitor of proteasome) were
analyzed by SDS-PAGE followed by western blotting using antibodies directed against CDK5 and p35 (Inputs). These extracts were then immunopurified using
anti-p35 antibody and analyzed by SDS-PAGE followed by western blotting using antibodies directed against p35 and CDK5 (IP: p35).level of p35, CDK5, and tau. These cells were first treated with
25 mM TMX or 0.25% DMSO during 6 hr. To verify that these
treatments did not modify the expression levels of CDK5 and
p35, their amounts were evaluated for the two conditions.
Although CDK5 expression was not modified, the level of p35
was lower in cells treated with TMX (Figure S1). Interestingly,
it was previously described that the inhibition of CDK5 activity
by (R)-roscovitine leads to stabilization of p35 (Sahlgren et al.,
2003). The opposite effect observed here for TMX underlines
that both drugs may have a different mode of interaction with
CDK5/p25. We then tested MG132, a proteasome inhibitor, to474 Chemistry & Biology 22, 472–482, April 23, 2015 ª2015 Elsevierblock the putative degradation of p35 induced by TMX treat-
ment. As shown in Figure 1D, treatment with MG132 stabilized
the level of p35 in TMX-treated cells compared with the result
obtained for DMSO. The cell extracts collected were then sub-
jected to immunoprecipitation using p35 antibody and analyzed
by SDS-PAGE followed by western blotting (Figure 1D). As ex-
pected, the level of CDK5 co-immunoprecipitated from the
TMX-treated cell extracts was significantly reduced in compari-
son with the one obtained for DMSO treatment, confirming the
modulation of CDK5/p25 interaction by TMX in the SK-N-BE(2)
neuroblastoma cell line.Ltd All rights reserved
Figure 2. TMX Inhibits CDK5/p25 Activity In Vitro and in Primary Neuronal Cells
(A) Increasing doses of TMX were added to GST-CDK5 in the reaction mixture (incubation: 5 min on ice) before adding 6xHis-p25 (incubation: 25 min on ice). The
kinase assay was then performed using histone H1 as substrate (incubation: 25 min at 30C) (mean ± SD, error bars represent SD, n = 3).
(B) 33.3 mM TMX was added to the reaction mixture before the formation of the dimer or after the formation of the dimer (light gray histograms) (mean ± SD, error
bars represent SD, n = 3). For comparison, the inactive compound was also added before the formation of the dimer (final concentration 33.3 mM).
(C) Increasing concentrations of ATPwere added to the kinase reactionmixture and the resulting IC50 values were calculated for (R)-roscovitine and TMX (mean ±
SD, error bars represent SD, n = 3).
(D) Analysis of the specificity of interaction between cellular components and the (R)-roscovitine affinity matrix by competition assay. Porcine brain extracts were
supplemented with various concentrations of chemical compounds (500 mM for (R)-roscovitine, 2 mM for ATP, and 500 mM for TMX) before loading on to im-
mobilized (R)-roscovitine. The bound proteins were analyzed by SDS-PAGE followed by western blotting using antibodies directed against CDK5 and p25.
(E) Left panel: treatment of primary neuronal cultures with 100 mM glutamate and increasing concentrations of MG132 over 5 hr has no consequence on the
expression level of phospho-tau (pTau). Right panel: in the presence of 100 mM glutamate and 20 mMMG132, the addition of increasing concentrations of TMX
decreases the phosphorylation of tau (pSer214). **Values are significantly decreased from DMSO. Mean ± SD, error bars represent SD, n (exposures) = 3.TMX Inhibits Pathogenic CDK5/p25 Kinase Activity by
Preventing the Formation of the Heterodimer
To validate the effect of TMX on the enzymatic activity of the
target, we used an in vitro assay to examine the kinase activity
of the CDK5/p25 recombinant complex. In order to mimic the
BRET assay protocol used in yeast, we mixed TMX with CDK5Chemistry & Biology 22,before adding p25. We next performed the protein kinase assay
in the presence of increasing doses of TMX. In good agreement
with the BRET experiments, we observed a dose-related inhibi-
tion of CDK5/p25 kinase activity by TMX, with a half maximal
inhibitory concentration (IC50) of 9.5mM (Figure 2A). As previously
observed for 3a-amino-5a-androstane (Corbel et al., 2011),472–482, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 475
Figure 3. TMXBinds to p25 and Not to CDK5
(A) Schematic representation of the binding of
N-Dides on CNBr-activated Sepharose through
the primary amine group.
(B) Increasing doses of N-Dides were added to
GST-CDK5 in the reaction mixture (incubation:
5 min on ice) before adding 6xHis-p25 (incubation:
25 min on ice). The kinase assay was then per-
formed using histone H1 as substrate (incubation:
25 min at 30C) (mean ± SD, error bars represent
SD, n = 3).
(C) A porcine brain extract was loaded on con-
trol (ethanolamine [Eth]) and N-Dides matrices.
Beads were extensively washed and the bound
proteins were analyzed by SDS-PAGE followed
by western blotting against CDK5, p35/p25, and
PKCa.another CDK5/p25 interaction inhibitor, TMX was less active
when added on a CDK5/p25 preformed complex (–84.45% ±
1.82% of the kinase activity on monomers; –31.07% ± 3.71%
on the preformed complex) (Figure 2B). In accordance with the
BRET assay, kinase activity was less affected in the presence
of InaCpd (–28.77% ± 14.4%).
To investigate the molecular mechanism of inhibition of the
CDK5/p25 kinase by TMX, we next performed in vitro experi-
ments with increasing doses of ATP in the kinase reaction
mixtures. ATP modulation did not modify the IC50 of TMX signif-
icantly, indicating that the drug acts as a non-ATP competitor to
inhibit kinase activity. As a control, with the same experimental
conditions, ATP modification produced an effect on the level of
kinase inhibition by (R)-roscovitine, a widely used ATP-mimetic
inhibitor of CDK5 (Figure 2C).
To confirm this non-ATPmimicmechanismof inhibition, affinity
chromatography was performed using (R)-roscovitine beads.
Porcine brain extracts containing CDK5 and p25 were supple-
mented with various concentrations of DMSO, (R)-roscovitine,
TMX, and ATP (Figure 2D). The signals corresponding to CDK5
and p25 disappeared in the presence of free (R)-roscovitine,
decreased with the addition of ATP, but were unaffected
by TMX. This confirms a different mode of binding of TMX to
CDK5/p25 in comparison with (R)-roscovitine, a prototypic mole-
cule for type I CDK inhibitors. To illustrate the non-conventional
mode of kinase inhibition by TMX, theworld’s largest commercial
kinase assay panel was assessed (KINOMEscan, DiscoveRx):
456 kinases belonging to the AGC, CAMK, CMGC, CK1, STE,
TK, and TKL families and representing more than 80% of the
human protein kinome were examined; 25 mM TMX was used.
KINOMEscan assays report true thermodynamic interaction
affinities, as opposed to IC50 values, which can depend on the
ATP concentration. This active site-directed competition binding
assay can detect multiple inhibitor types, including type I, type II,
and allosteric. None of the kinases tested, including protein
kinase C (PKC) isoforms (PRKCD, PRKCE, PRKCH, PRKCI,
and PRKCQ) was strongly affected by TMX (Figure S2; Table S1).
For a more relevant model than neuroblastoma cell lines, vali-
dation of the effects of TMX on CDK5/p25 activity was then veri-
fied using primary neuronal cultures. CDK5 is a tau kinase and
treatment with TMX should lead to a decrease in tau phosphor-476 Chemistry & Biology 22, 472–482, April 23, 2015 ª2015 Elsevierylation. Cells expressing the p25 subunit were preferred as the
CDK5/p25 complex is more stable than CDK5/p35 (Patrick
et al., 1999) and is thus more likely to have robust activity. As
p25 was weakly expressed in primary cortical neuron cultures,
cleavage of p35 was induced by glutamate, an excitatory amino
acid involved in p25 production (Lee et al, 2000) (the appearance
of p25 was verified by SDS-PAGE followed by western blotting;
Figure S3). The proteasome inhibitor MG132 was used (Fig-
ure 2E) to avoid degradation of the protein p25 as previously
observed after chemical treatments (Figure 1D). The addition
of MG132 had no effect on the phosphorylation of tau
(pSer214), a residue phosphorylated by CDK5 (Figure 2E, left
panel) (Liu et al., 2002). In the presence of MG132 and increasing
concentration of TMX, a decrease in tau phosphorylation was
observed (Figure 2E, right panel). This decrease was significant
in comparison with the variation observed for the signal of the
anti-tau46 antibody, which recognizes all tau isoforms. This sug-
gests that modification of the tau phosphorylation level probably
results from a lower CDK5 kinase activity, itself caused by inhibi-
tion of the CDK5/p25 interaction by TMX.
TMX Binds to p25 and Not to CDK5
With the aim of detecting TMX targets, affinity chromatography
was used. We took advantage of a product of TMX meta-
bolism, N,N-didesmethyl-TMX (N-Dides) (Figure 3A), as already
described (O’Brian et al., 1988a). N-Dides was coupled to CNBr-
activated Sepharose through its primary amine. In order to check
thatN-Dideswasstill active, its effectonCDK5/p25kinaseactivity
was measured (Figure 3B). Kinase activity of CDK5 was also
affectedbyN-Dides (IC50 = 4mM) (Figure 3B).Hence, affinity chro-
matography using this immobilized metabolite was suitable for
studying TMX selectivity. Porcine brain extract was used as the
protein source, as it contains desired targets of TMX: CDK5,
p35, p25, and PKCa (protein kinase C a) (Figure 3C, left panel).
PKCa was used as control as its binding to TMX has already
been described (O’Brian et al., 1988a). The signal obtained using
anti-PKCa antibody indicated that the N-Dides matrix was func-
tional. In addition, western blot analysis revealed the presence
of p35 and p25 on the beads, whereas CDK5 was absent (Fig-
ure 3C, right panel). This experiment revealed that TMX can bind
to the p35 or p25 activators, rather than to the CDK5 monomer.Ltd All rights reserved
Figure 4. Biophysical Characterizations of the p25-TMX Complex
(A) Fluorescence emission spectra of free p25 (blue) and TMX-bound p25
forms (red) in 50 mM Tris-HCl (pH 7.5), 140 mM KCl, 0.1 mM EDTA, 1 mM
DTT, 10% glycerol, 20C. Fluorescence emission spectrum of free TMX
is shown in gray. The arithmetic sum of the free forms of p25 and TMX is
also displayed (purple) for comparison with the complex experimental
spectrum. Excitation wavelength is 290 nm, protein concentration 1 mM, TMX
1.5 mM.
Chemistry & Biology 22,Binding Mode of TMX on the p25 Protein Surface
The protein p25 contains three tryptophanyl residues among its
208 residues: W177, W190, and W258 (numbering of residues
referring to the entire p35 protein chain). Figure 4A displays
the tryptophan fluorescence emission spectrum of p25 in the
absence and in the presence of TMX. Upon addition of TMX to
a p25 solution, a decrease in the tryptophan emission spectrum
was observed. This result confirmed that TMX interacts with p25
with subsequent conformational changes within the protein.
Whatever the protein binding status, free or complexed, the
maximal emission wavelength of the fluorescent tryptophan res-
idues remains at 335nm; it can be inferred that the conforma-
tional modifications induced by the binding to TMX do not affect
protein polarity in the surroundings of these aromatic residues. In
addition, TMX excited at 290 nm exhibited two emission bands
at 366 and 386 nm. The intensity of these bands was increased
upon TMX binding to p25. This enhancement might result from a
non-radiative energy transfer from tryptophan to TMX, which im-
plies that these two fluorophores are close to each other and/or
that modification of the emission transition dipole moments of
TMX occurs. In the latter case, the decrease in emission of the
tryptophans could be due to the presence of side chains in the
vicinity of one or some tryptophanyl residues, which would
quench the Trp emissions within the p25-TMX complex.
Interaction of p25 with TMX was further confirmed by TMX nu-
clear magnetic resonance (NMR) spectroscopy in the absence
or presence of p25. In a first series of experiments, titration of
the p25 protein into the TMX solution resulted in chemical shift
perturbations and broadening of several peaks of the chemical
compound in a dose-dependent manner (Figure 4B). Perturba-
tions of the signal could be observed in the region of aromatic
proton resonances in the TMX spectrum, indicative of binding
of the protein to these moieties (Figures 4B and 4C; Figure S4).
The aliphatic region showed additional perturbations of the
signals, indicating that most of the molecule is implicated in
the interaction. In addition, saturation transfer experiments
were performed with the sample containing TMX mixed with
p25 in a 10:1 ratio. The protein was saturated by an impulsion
at –1 ppm, a frequency outside the TMX range. This saturation
will thus be transferred to the small molecule by spin diffusion
only if it is bound by the protein. In addition, an off-resonance
spectrum of TMX was acquired as a control spectrum with satu-
ration at 300 ppm, outside the resonance range of both TMX and
p25. Detection of several signals in the red difference spectrum
(Figure 4C) between the on and off-saturation experiments
confirmed the interaction. Signals corresponding to aromatic
protons and aliphatic protons (Figure S4) could be identified in
the difference spectrum, indicating the involvement of these
chemical moieties in the binding.
In silico analysis revealed that TMX can dock to an active site
on p25, where the amino acids of the C-helix of CDK5 (Figure 5A)
are accommodated. This in silico docking is congruent with the(B) 1D NOESY spectra of TMX showing signals of the aromatic moieties
from bottom to top: 100 mM TMX without p25, and with 1.2 mM, 2.5 mM, and
10 mM p25.
(C) Superposition of the same aromatic region of the 1D NOESY 1H spectrum
of TMX (in red) and the saturation difference in the presence of 10 mM p25,
overlaid in purple.
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Figure 5. In Silico Analysis of the TMX Bind-
ing on p25
(A) Left panel: two hot spots are described between
p25 andCDK5. The hot spot studied here concerns
the aC helix of CDK5 (in red) (which contains the
conserved motif of CDKs: PSAALRE) and p25.
Right panel: the positively/negatively charged
sections of the p25 surface are depicted in red and
blue, respectively. A cavity, which can host TMX, is
observed on the p25 surface.
(B) The conformational changes and deviations of
the a helix. The original conformation of p25 is
colored in cyan and the structure from the molec-
ular dynamics simulations is wheat colored. Amino
acids from the original p25 are in red and those
from the simulations are in purple. The structures of
TMX are omitted for clarity.
(C) Representations of the binding patterns of TMX
on the protein p25 obtained after dynamic simula-
tions. TMX is represented in green and the Trp in
position 258 is purple. The right panel shows the
proximity between TMX and the protein, and more
particularly with Trp258 (5.17 and 5.60 A˚).affinity chromatography experiment (Figure 3). The portion of the
drug linked toSepharose extends toward the solvent, compatible
with the binding of TMX targets. According to our simulations,
most of theprotein stayed stable during thedynamics processes;
compared with the original p25 structure, only certain deviations
or conformational changes were observed in the a helix around
the active site in the simulated protein. For example, as seen in
Figure 5B, the deviation of a5 and a6 is obvious. Due to the
conformational changes in the tail of a3, Tyr236 deviated from
the original position by a distance of 6.4 A˚. All these deviations
or conformational changes were caused by the binding of TMX
to p25. The conformational change of Trp258 is shown in Fig-
ure 5C; the distance between the side chain of the residue in
the new position and TMX is less than 6 A˚.
DISCUSSION
Here we report that TMX (Jordan, 2003), the gold standard for
endocrine treatment of all stages of estrogen-receptor-positive478 Chemistry & Biology 22, 472–482, April 23, 2015 ª2015 Elsevier Ltd All rights reservedbreast cancer, inhibits CDK5 kinase
activity by blocking the binding of
CDK5 to its regulatory subunit p35 or its
N-terminal truncated form p25. The inhi-
bition of CDK5 is crucial as this kinase
is involved in numerous pathological
processes (neurodegenerative diseases
such as tauopathies, pancreatic and
prostatic cancers, lung cancer). Although
TMX is successfully used in the clinic for
the treatment of cancer, it was initially
identified in the early 1960s as a con-
traceptive agent (Harper and Walpole,
1967). The first targeted medicine for
breast cancer is in fact the result of a
therapeutic repositioning. The chemicallibrary screened in this study was designed to enable drug
repositioning.
Our present findings add CDK5/p35 and CDK5/p25 to the
selectivity pattern of TMX (Figure 6) and could be useful to inter-
pret its cellular actions in a more detailed manner. TMX is a
triphenylethylenic selective estrogen receptor modulator; it
acts mainly via estrogen receptors (ER). TMX is cytostatic on
ER-positive cell lines at low concentrations closed to its binding
affinity (Kdz 1 nM) for ER. At higher concentrations (1–10 mM),
the cytotoxic effect of TMX is not reversed by the natural ligand
of ER, 17b-estradiol (E2), suggesting other targets (de Medina
et al., 2004). Studies on the pharmacological selectivity of TMX
have indicated that this cellular effect can be explained through
nanomolar to micromolar affinity binding to various other cellular
components (Figure 6).
The kinase activity of CDK5 is not only linked to neurodegen-
erative disease but also to cancer. Studies have shown that
CDK5 promotes glioblastoma cell migration and invasion by
phosphorylation of phosphatidylinositol 3-kinase enhancer-A
Figure 6. TMX and Its Main Targets
Acyl-coenzyme A:cholesterol acyltransferase (ACAT); protein kinase C (PKC);
calmodulin (CaM)-dependent enzymes (Calmodulin); estrogen receptor (ER);
microsomal anti-estrogen binding site (AEBS). Adapted from de Medina et al.
(2004).GTPase. This increased glioblastoma cell migration can be
significantly attenuated by roscovitine (Liu et al., 2008), a chem-
ical compound also used in the present study as an ATP-mimetic
inhibitor of CDK5 (Figure 2). Interestingly, TMX can significantly
inhibit human glioblastoma cell invasion in vitro. This effect is
linked to the inhibition of protein kinase C (PKC) activity as
described by the authors (Zhang et al., 1997). The inhibition of
PKC was the mechanism suspected to mediate the cellular ef-
fect of TMX on cancer cell migration. This mechanism was
used for phase 2 clinical trials conducted with TMX for glioma
treatment (Rich and Bigner, 2004). The level of PKC inhibition
by TMX varies from 25 mM to 100 mM (O’Brian et al., 1985,
1986). TMX inhibits PKC by binding to the ATP-binding region
of the active site as observed by affinity chromatography
(O’Brian et al., 1988b). In our present study, we obtained an N-
Dides matrix in order to purify both PKCa and the p25 activating
subunit fromporcine brain (Figure 3). Our results suggest that the
inhibition of CDK5/p25 could contribute to the antitumor effect of
TMX. Additional studies will be needed to fully understand the
contribution of this inhibition to the overall effect of the drug on
glioblastoma cells.
The BRET-based screening assay used in our study is
well adapted for the discovery of protein-protein interaction
inhibitors. One of the main challenges in pharmacology is
to characterize selective inhibitors that bind with high affinity
to a specific target without significantly affecting similar pro-
tein targets. By binding to the protein surface distant from the
ATP-binding site, TMX targets a less conserved region. Our
previous work (Corbel et al., 2011; Zhang et al., 2011) has
shown that destabilization of the dimer with small chemical
drugs (3a-amino-5a-androstane) seems to be very hard to
observe, because all the characterized compounds are
inactive on the CDK5/p25 preformed dimer. The inability of
TMX to disrupt preformed CDK5/p25 complexes (Figure 2B)
highlights the principle that screening small molecules againstChemistry & Biology 22,non-preformed protein complexes is likely to increase hit
rates.
Another non-ATP competitive-based strategy has been devel-
oped previously to inhibit CDK5 selectively (Sundaram et al.,
2013) by a peptide (CIP) derived from p35. CIP specifically
inhibits hyperactivation of CDK5 both in vitro and in cellular as-
says. Interestingly, the sequence of this peptide contains resi-
dues 157–279 of p35, including the Trp258 putatively involved
in the interaction with TMX as revealed by our in silico and fluo-
rescence experiments (Figure 5B). The inhibition by CIP showed
that it is possible to specifically modulate CDK5/p25 kinase ac-
tivity without significantly affecting the CDK5/p35 dimer (Sun-
daram et al., 2013). Nevertheless, and despite the specificity
for the pathogenic dimer CDK5/p25, CIP is clearly not adapted
for human therapy compared with small chemical molecules.
However, its high specificity clearly demonstrates the potential
of using a non-ATP competitor as inhibitor of CDK5/p25.
Although TMX is a marketed drug, medicinal chemistry and
structure-activity relationship (SAR) studies would be beneficial
to characterize TMX derivatives that can specifically block the
CDK5/p25 interaction with higher efficiency. The neuroprotec-
tive effect of TMX has already been described (O’Neill et al.,
2004) and attributed to the partial estrogen agonist role of TMX
in the brain. The data described in this article suggest that a
CDK5-dependent mechanism may contribute to this effect.
To ensure that the reduction of CDK5/p25 dimer formation re-
sulted in decreased phosphorylated forms of tau, we performed
western blot analysis using phospho-tau antibodies directed
against pSer214. Despite the fact that Ser214 is not followed
by a proline residue, this site seems to be affected by
inhibition of CDK5 by TMX. Phosphorylation of non-(Ser/Thr)
Pro sequences by CDK5 are reported in the literature:
Ser20 (PLSQETFsDLWKLLP) (Ajay et al., 2010) and Ser15
(PSVEPPLsQETFSDL) (Lee et al., 2007) of p53; Thr197
(ILTPKKHtVKKRIGS) of Rho family GTP-binding protein TC10al-
pha (Okada et al., 2008). Moreover, the phosphorylation of tau on
Ser214 by CDK5 has also been reported (Liu et al., 2002). These
data indicate that Ser214 should be considered as a bona fide
marker of CDK5 kinase activity.
Surprisingly, a recent study indicates that the p25 subunit pref-
erentially binds and activates glycogen synthase kinase 3b
(GSK3b) (Chow et al., 2014). GSK3b phosphorylates tau and its
3D structure is remarkably similar to CDK5. The four residues of
p25 predicted to establish hydrogen bonds with GSK3b
(Trp190, Gly238, Met237, and Asp259) surround the predicted
site that accommodates TMX, as depicted in Figure S5. One of
our aims now is to analyze biochemically the effect of TMX on
the GSK3b/p25 interaction. In the context of discovery of small
molecular size protein-protein interaction inhibitors, our study
sheds light on a very important hot spot on the p25 surface. This
region of p25 can be considered as a starting point for further
development of new potent and selective pharmacological inhib-
itors.Our studyprovidesagood illustrationof the relevanceofpro-
tein-protein interactions as therapeutic targets of great potential.
A therapeutic link between TMX and AD was already under-
lined in an epidemiologic study (Breuer and Anderson, 2000).
Observations on 93,031 women (at least 65 years old) revealed
that women receiving TMX were less likely to be diagnosed
with Alzheimer’s disease. It is estimated that more than472–482, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 479
400,000 women are alive today as a result of TMX therapy. Our
study suggests that this fascinating molecule might bring new
benefits to human kind in the future by inspiring new treatments
against neurodegenerative diseases.
SIGNIFICANCE
CDK5 activity is misregulated following its interaction with
the pathological subunit p25. Most drug-like inhibitors of
CDK5/p25 already described target the ATP-binding pocket
and consequently are mostly poorly selective. Inhibition
of side targets could lead to side effects that are non-
compatible with treatment of human neuropathies such
as Alzheimer’s disease (AD). To address this problem, a
BRET-based screening assay has been developed with the
aim of characterizing inhibitors of the CDK5/p25 interaction.
Among the compounds screened, TMX, a generic drug
used for breast cancer treatment, was characterized as a
hit molecule. We showed here that TMX acts by binding on
the protein p25 subunit and that TMX treatment of neuronal
cells modulates the pattern of tau phosphorylation, a known
substrate of CDK5/p25 and one of the neuropathological hall-
marksofAD. This study reveals that TMXbinds toadruggable
hot spot on the p25 surface. This hot spot can be used to
develop new therapeutic strategies for CDK5/p25-related
diseases.
EXPERIMENTAL PROCEDURES
Chemicals
MG132 (no. C2211), glutamate (no. G1251), TMX (no. T5648), and 17b-estra-
diol (no. E8875) were purchased fromSigma. DMSO (no. 472301, Sigma) is the
drug vehicle used in this study.
BRET Assay in Yeast
BRET signals were measured as described previously in Corbel et al. (2011)
(see Supplemental Information for details).
Neuroblastoma Cell Line Culture
The SK-N-BE(2) human neuroblastoma cell line was kindly provided by
Dr. J. Bernard (UMR8126, Institut Gustave Roussy, Villejuif, France). Cells
at 60% confluence were treated with 30 mM MG132 and 25 mM chemical
compounds for 6 hr before lysis. Crude protein extracts were prepared in
RIPA buffer (Supplemental Information) and analyzed by SDS-PAGE fol-
lowed by western blotting or after immunoprecipitation using anti-p35
antibody.
Protein Kinase Assays
The recombinant mammalian proteins CDK5 and p25 are expressed in
Escherichia coli as a GST-fusion (GST-CDK5) or a His-tagged protein
(6xHis-p25). These two proteins were purified using glutathione agarose
(no. G4510, Sigma) and Ni-NTA agarose (no. 30210, Qiagen) matrices
following the manufacturers’ recommendations. To perform the kinase
activity measurements, the two proteins were mixed separately (dimer in
formation) or together (dimer formed) before adding the compound studied.
Then, the kinase activities were assayed using histone H1 as substrate
in buffer C (Supplemental Information) for 25 min at 30C, at a final ATP
concentration of 15 mM. For the ATP competition assays, the final concen-
tration of ATP was modified. To measure the IC50, the curve fitting software
SigmaPlot and the Miller curve fitting algorithm were used. These experi-
ments were performed on the Kinase Inhibitor Specialized Screening facility
(KISSf), a member of Biogenouest (Western France Life Science and Environ-
ment Core Facility Network).480 Chemistry & Biology 22, 472–482, April 23, 2015 ª2015 ElsevierAffinity Chromatography on Immobilized Matrices
(R)-Roscovitine and N-Dides affinity matrices were used according to the pro-
tocol previously described in Bach et al. (2005) (see Supplemental Information
for details).
Electrophoresis and Western Blotting
Details on the classical protocols used are provided in the Supplemental Infor-
mation. The primary antibodies used were p35/p25 (no. sc-820; Santa Cruz
Biotechnology), CDK5 (no. sc-173; Santa Cruz Biotechnology), GST (no. sc-
138; Santa Cruz Biotechnology), PKCa (no. 2056; Cell Signaling), tau (T46:
no. 13-6400, Invitrogen), phospho-tau (pSer214: no. 54967, Anaspec), and
b-actin (no. A5441, Sigma).
Ethics Approval
All animal care procedures were reviewed by the Institutional Animal Care
Committee at the University of California, Santa Barbara, and found to be in
compliance with guidelines on animal care.
Primary Cortical Neuronal Cultures
E18pregnant Sprague-Dawley rats were purchased fromCharlesRiver Labora-
tories. Embryos were surgically removed and their cortices were dissected and
cultured as described in Nikolic et al. (1996). Cortical cultures were grown in
basal growthmediumonsix-well plates coatedwithpoly-D-lysine; 400,000 cells
were plated per well. Treatments with glutamate, MG132, and chemical com-
poundswere performed 10 days after plating for 5 hr. The corresponding proto-
col is described in Lee et al. (2000). The cells were then retrieved, lysed in RIPA
buffer, and the corresponding proteins were analyzed by western blotting.
Emission Spectrum of Tryptophanyl Residues of Free and TMX-
Bound p25 Protein
Experiments were carried out with 1 mM purified 6xHis-p25 and 1.5 mM TMX
prepared in buffer A (Supplemental Information). The protein concentration
was determined by absorbancy measurements at 280 nm, using a molar
extinction coefficient of 26,930 M1 cm1. Trp fluorescence emission spectra
were collected with an SLM 8100 spectrofluorometer at an excitation wave-
length of 290 nm and 20C. The optical path lengths were 0.4 cm for the exci-
tation and 1 cm for the emission. The bandwidths of the excitation and the
emission slits were 2 nm. The emission spectra were collected with 1 nm
wavelength increments and the fluorescence intensities were corrected for
the buffer contribution.
NMR
1D proton spectra were recorded on a 900-MHz spectrometer equippedwith a
cryoprobe head. TMX was first suspended in DMSO-d6 before dilution into the
NMR buffer (Supplemental Information). Selective saturation of protein reso-
nances was done at –1 ppm or –900 Hz (saturation on spectrum) to excite
the protein but not TMX. A control experiment was performed with TMX alone
to ensure that the –1 ppm saturation pulse did not reach the compound. Off-
saturation pulses were performed at 300 ppm. Spectra were acquired with
512 scans. Data processing and analysis was performed using Topspin 2.1.
The proton TMX signal assignment is published in Cai et al. (2010).
Docking and Molecular Dynamics Simulations
The structure of p25 was obtained from the CDK5/p25 complex (PDB code:
1UNL) and the docking of TMX to the protein, energy filtering, and ranking
were performed using the Glide module in the Schrodinger software suite
(Friesner et al., 2004). The CA atom of Leu49 of CDK5was adopted as the cen-
ter of the enclosing docking box to confine TMX. Themolecular dynamics sim-
ulations were carried out using the Amber 9.0 (Case et al., 2006) software suite
with the all-atom force field of Cornell et al. (1995). A 2-fs time step was used
and long-range electrostatic interactions were treated with the particle mesh
Ewald procedure (Darden et al., 1993) using a cubic B-spline interpolation
and a 105 tolerance for the direct space, and with a 12-A˚ non-bonded cutoff.
Minimization consisted of four steps and all the heavy atoms in the p25/TMX
complex were restrained with degressive forces of 500, 100, and 5 kcal/mol,
respectively. The production parts of all the systems took 10 ns in the NPT
ensemble at 300 K with Berendsen temperature coupling and at constantLtd All rights reserved
pressure (1 atm) with isotropic molecule-based scaling (Berendsen et al.,
1984).Statistical Analysis
Data were expressed as means ± SD. Statistical analyses were done by Stu-
dent’s t test and significance levels are *p<0.05; **p<0.01; n.s., not significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2015.03.009.AUTHOR CONTRIBUTIONS
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